Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00071279 | SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis | PHASE3 | COMPLETED | 1,215 | — | — | Nov 1, 2003 | Dec 1, 2005 | Apr 6, 2011 | 65 | United States, Australia +18 |
| NCT00062803 | SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism | PHASE3 | COMPLETED | - | — | — | Jun 1, 2003 | Oct 1, 2005 | Apr 29, 2009 | 93 | United States, Argentina +18 |
| Name | Type | Description |
|---|---|---|
| SR34006 (idraparinux sodium) Injection | DRUG | - |
| SR34006 | DRUG | - |
| (LMW)heparin | DRUG | - |
| Warfarin VKA | DRUG | - |
| Acenocoumarol VKA | DRUG | - |
Inclusion Criteria: * Patients with confirmed symptomatic Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) who have been treated with acenocoumarol, warfarin or SR34006 for six months * Written informed consent Exclusion Criteria: * Legal age limitations (country specific) * Indication for a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| ICON Plc | ICLR | 1 | NA | Undisclosed |
| Penumbra, Inc. | PEN | 1 | — | Undisclosed |
| Boston Scientific Corporation | BSX | 1 | — | Undisclosed |
| AngioDynamics, Inc. | ANGO | 2 | NA | Undisclosed |
| Universidade do Porto | OSTX | 1 | — | Undisclosed |